These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 27587380)
21. Safety and efficacy of blinatumomab: a real world data. Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826 [TBL] [Abstract][Full Text] [Related]
22. Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland. Deeren D; Balabanov S; Nickel K; Giannopoulou C; Gonzalez-McQuire S; Kutikova L; Bouwmeester W; Spyridonidis A Leuk Res; 2020 Apr; 91():106334. PubMed ID: 32135394 [TBL] [Abstract][Full Text] [Related]
23. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185 [TBL] [Abstract][Full Text] [Related]
24. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review. Dombret H; Thomas X; Chevallier P; Nivot E; Reitan J; Barber B; Barlev A; Mohty M J Med Econ; 2016 Nov; 19(11):1034-1039. PubMed ID: 27207188 [TBL] [Abstract][Full Text] [Related]
25. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983 [TBL] [Abstract][Full Text] [Related]
26. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Thomas DA; Kantarjian H; Smith TL; Koller C; Cortes J; O'Brien S; Giles FJ; Gajewski J; Pierce S; Keating MJ Cancer; 1999 Oct; 86(7):1216-30. PubMed ID: 10506707 [TBL] [Abstract][Full Text] [Related]
27. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508 [TBL] [Abstract][Full Text] [Related]
28. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536 [TBL] [Abstract][Full Text] [Related]
32. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811 [TBL] [Abstract][Full Text] [Related]
33. Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort. Silva WF; Silverio A; Duarte BKL; Aguiar TF; Bendlin RM; Massaut IHB; Pagnano KBB; Velloso EDRP; Rocha V; Rego EM Leuk Res; 2021 Nov; 110():106666. PubMed ID: 34274856 [TBL] [Abstract][Full Text] [Related]
34. Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study. Bassan R; Hoelzer D; Thomas X; Montesinos P; Pavlu J; McKendrick J; Kudlac A; Barlev A; Barber B; Cong Z Adv Ther; 2019 Apr; 36(4):870-879. PubMed ID: 30847777 [TBL] [Abstract][Full Text] [Related]
35. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422 [TBL] [Abstract][Full Text] [Related]
39. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant. Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P Front Immunol; 2023; 14():1191382. PubMed ID: 37469510 [TBL] [Abstract][Full Text] [Related]
40. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]